Metastatic Uveal Melanoma Therapeutics Market Size, Emerging Trends, Forecasts

Comments · 93 Views

Uveal Melanoma is a rare intraocular tumour in adults which originates in either iris, ciliary body, or choroid. Around 50% of the people develop metastatic disease after uveal melanoma diagnosis. It metastasizes to the liver and carries poor prognosis.

Stratview Research delivers key insights on the global Metastatic Uveal Melanoma Therapeutics Market. According to Stratview Research, the market is segmented By Type (Sunitinib Malate, Vincristine Sulfate Liposomal, LY-2801653, Sotrastaurin Acetate, Others), By Application (Hospital, Clinic, Others), and Region.

Market Insights

The growth of the global metastatic uveal melanoma therapeutics market is driven by increasing incidences of uveal melanoma cancer. The increasing geriatric population across geographies is likely to propel market growth at a significant rate during the review period. The market players are continuously emphasizing developing advanced solutions to treat the disease, which, is likely to drive the market growth significantly.

Market Segments' Analysis

By end-user, the metastatic uveal melanoma therapeutics market has been bifurcated into hospitals, clinics, and others. Under these, the hospitals' segment garnered the largest market share in 2020 and is projected to grow at the highest CAGR during the review period. The segment growth can be attributed to increasing incidences of metastatic disease and the availability of required infrastructure in the hospitals.

By region, the market in North America garnered the largest market share in 2020 and is projected to grow at a steady CAGR during the assessment period. The US accounted for the larger market share in the region due to rising cases of uveal melanoma. Around 5.2 cases per 1 million population are reported every year. The market in Asia-Pacific is projected to register a healthy growth rate on account of growing medical tourism and increasing consumer awareness about cancer and its treatment methods.

Key Players

The following are some of the key players in the Metastatic Uveal Melanoma Therapeutics Market:

  • AstraZeneca PLC (UK),
  • Eli Lilly and Company (The U.S),
  • Novartis International AG (Switzerland),
  • Pfizer Inc. (The U.S),
  • Spectrum Pharmaceuticals, Inc. (The U.S),
  • Amgen, Inc. (The U.S),
  • Hoffmann-La Roche AG (Switzerland),
  • Bristol-Myers Squibb Company (The U.S),
  • Merck Co., Inc. (The U.S),
  • Daiichi Sankyo Company, Limited (Japan), and
  • AB Sciences (France).

Get a free sample report here: https://www.stratviewresearch.com/Request-Sample/1810/metastatic-uveal-melanoma-therapeutics-market.html#form

About Us –

Stratview Research is a leading global market research firm providing expert research solutions, trusted by clients worldwide. To keep our clients ahead of the curve, we provide data backed by extensive market research and in-depth industry knowledge. The broad spectrum of integrated insights is referred to, and cited by press releases, interview with key players, white papers, journals, etc. Stratview research also offers custom research services across the sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please connect with our team.

Get in touch with us for more details –

Call: +1-313-307-4176 Or Mail Us:  [email protected]

Comments